155 related articles for article (PubMed ID: 24090996)
41. NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.
Dastur A; Choi A; Costa C; Yin X; Williams A; McClanaghan J; Greenberg M; Roderick J; Patel NU; Boisvert J; McDermott U; Garnett MJ; Almenara J; Grant S; Rizzo K; Engelman JA; Kelliher M; Faber AC; Benes CH
Clin Cancer Res; 2019 Jan; 25(1):312-324. PubMed ID: 30224339
[TBL] [Abstract][Full Text] [Related]
42. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1.
Li X; Gounari F; Protopopov A; Khazaie K; von Boehmer H
J Exp Med; 2008 Nov; 205(12):2851-61. PubMed ID: 18981238
[TBL] [Abstract][Full Text] [Related]
43. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis.
Gu L; Zhou C; Liu H; Gao J; Li Q; Mu D; Ma Z
J Exp Clin Cancer Res; 2010 Nov; 29(1):150. PubMed ID: 21083937
[TBL] [Abstract][Full Text] [Related]
44. MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context.
Kleppe M; Mentens N; Tousseyn T; Wlodarska I; Cools J
Haematologica; 2011 May; 96(5):779-83. PubMed ID: 21193420
[TBL] [Abstract][Full Text] [Related]
45. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
[TBL] [Abstract][Full Text] [Related]
46. Flavone inhibited proliferation of T-ALL by promoting c-Cbl-induced ubiquitinylation and degradation of Notch1.
Zhu W; Zhu Y; Xu H; Wang T; Wang J; Meng M; Liu Y; Yan H; Yang Q; Liu P
Biochem Biophys Res Commun; 2020 Feb; 522(3):684-689. PubMed ID: 31785807
[TBL] [Abstract][Full Text] [Related]
47. RNA interference-mediated silencing of NANOG leads to reduced proliferation and self-renewal, cell cycle arrest and apoptosis in T-cell acute lymphoblastic leukemia cells via the p53 signaling pathway.
Cao J; Li L; Chen C; Lv C; Meng F; Zeng L; Li Z; Wu Q; Zhao K; Pan B; Cheng H; Chen W; Xu K
Leuk Res; 2013 Sep; 37(9):1170-7. PubMed ID: 23683786
[TBL] [Abstract][Full Text] [Related]
48. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
[TBL] [Abstract][Full Text] [Related]
50. Suppression of leukemia development caused by PTEN loss.
Guo W; Schubbert S; Chen JY; Valamehr B; Mosessian S; Shi H; Dang NH; Garcia C; Theodoro MF; Varella-Garcia M; Wu H
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1409-14. PubMed ID: 21212363
[TBL] [Abstract][Full Text] [Related]
51. Developmental strategies for evasion of Arf tumor suppression.
Volanakis EJ; Sherr CJ
Cell Cycle; 2010 Jan; 9(1):14-5. PubMed ID: 20009580
[No Abstract] [Full Text] [Related]
52. The clerodane diterpene casearin J induces apoptosis of T-ALL cells through SERCA inhibition, oxidative stress, and interference with Notch1 signaling.
De Ford C; Heidersdorf B; Haun F; Murillo R; Friedrich T; Borner C; Merfort I
Cell Death Dis; 2016 Jan; 7(1):e2070. PubMed ID: 26821066
[TBL] [Abstract][Full Text] [Related]
53. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1.
Ashworth TD; Pear WS; Chiang MY; Blacklow SC; Mastio J; Xu L; Kelliher M; Kastner P; Chan S; Aster JC
Blood; 2010 Dec; 116(25):5455-64. PubMed ID: 20852131
[TBL] [Abstract][Full Text] [Related]
54. Cyclophosphamide inhibits Pax5 methylation to regulate the growth of retinoblastoma via the Notch1 pathway.
Jin L; Ma X; Lei X; Tong J; Wang R
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S497-S508. PubMed ID: 34658283
[TBL] [Abstract][Full Text] [Related]
55. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches.
Ma W; Gutierrez A; Goff DJ; Geron I; Sadarangani A; Jamieson CA; Court AC; Shih AY; Jiang Q; Wu CC; Li K; Smith KM; Crews LA; Gibson NW; Deichaite I; Morris SR; Wei P; Carson DA; Look AT; Jamieson CH
PLoS One; 2012; 7(6):e39725. PubMed ID: 22768113
[TBL] [Abstract][Full Text] [Related]
56. Role of Triggering Receptor Expressed on Myeloid Cell-1 Expression in Mammalian Target of Rapamycin Modulation of CD8
Cui N; Wang H; Su LX; Zhang JH; Long Y; Liu DW
Chin Med J (Engl); 2017 May; 130(10):1211-1217. PubMed ID: 28485322
[TBL] [Abstract][Full Text] [Related]
57. Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells.
Wang X; Lou K; Song X; Ma H; Zhou X; Xu H; Wang W
Toxicol Appl Pharmacol; 2020 Jun; 396():115001. PubMed ID: 32277947
[TBL] [Abstract][Full Text] [Related]
58. L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.
Rosilio C; Nebout M; Imbert V; Griessinger E; Neffati Z; Benadiba J; Hagenbeek T; Spits H; Reverso J; Ambrosetti D; Michiels JF; Bailly-Maitre B; Endou H; Wempe MF; Peyron JF
Leukemia; 2015 Jun; 29(6):1253-66. PubMed ID: 25482130
[TBL] [Abstract][Full Text] [Related]
59. miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia.
Saccomani V; Grassi A; Piovan E; Bongiovanni D; Di Martino L; Minuzzo S; Tosello V; Zanovello P
Cells; 2020 Jul; 9(7):. PubMed ID: 32708470
[TBL] [Abstract][Full Text] [Related]
60. Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways.
Nagai T; Ohmine K; Fujiwara S; Uesawa M; Sakurai C; Ozawa K
Leuk Res; 2010 Aug; 34(8):1057-63. PubMed ID: 20071026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
